Along with the growing heterogeneity of the American population, ethnic/racial disparity is becoming a clear health issue in the United States. The awareness of ethnic/racial disparities has been growing because of considerable data gathered from recent clinical and epidemiological studies. These studies have highlighted the importance of addressing these differences in the diagnosis and treatment of various diseases potentially according to race. It is becoming particularly clear that there is a 2- to 3-fold racial difference in certain cardiovascular diseases (eg, preeclampsia) associated with dysfunctional nitric oxide—mediated vasodilation. In this review, the authors summarize the current literature on racial disparities in nitric oxide—mediated vasodilation in relation to cardiovascular health with an emphasis on vascular nitric oxide bioavailability as a balance between production via endothelial nitric oxide synthase and degradation through reactive oxygen species. The major hypotheses postulated on the biological basis of these differences are also highlighted.
Furchgott RF , Zawadzki JVThe obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-376.
Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G.Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A. 1987;84:9265-9269.
4.
Kubes P., Suzuki M., Granger DNNitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA. 1991;88:4651-4655.
5.
Radomski MW, Palmer RM, Moncada S.The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium . Biochem Biophys Res Commun.1987;148:1482-1489.
6.
Garg UC, Hassid A.Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest.1989;83:1774-1777.
7.
Contestabile A., Ciani E.Role of nitric oxide in the regulation of neuronal proliferation, survival and differentiation. Neurochem Int. 2004;45:903-914.
8.
Toda N., Ayajiki K., Okamura T.Nitric oxide and penile erectile function. Pharmacol Ther.2005;106:233-266.
9.
Scherrer U., Sartori C.Defective nitric oxide synthesis: a link between metabolic insulin resistance, sympathetic overactivity and cardiovascular morbidity. Eur J Endocrinol.2000;142: 315-323.
10.
Keeble JE, Moore PKPharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal antiinflammatory and related nitric oxide-donating drugs. Br J Pharmacol.2002;137:295-310.
11.
Tuteja N., Chandra M.,Tuteja R., Misra MKNitric oxide as a unique bioactive signaling messenger in physiology and pathophysiology. J BiomedBiotechnol.2004;2004:227-237.
12.
Rauhala P., Andoh T., Chiueh CCNeuroprotective properties of nitric oxide and S-nitrosoglutathione. Toxicol Appl Pharmacol.2005;207:91-95.
13.
de la Torre JC, Aliev G.Inhibition of vascular nitric oxide after rat chronic brain hypoperfusion: spatial memory and immunocytochemical changes . J Cereb Blood Flow Metab. 2005;25:663-672.
14.
Ricciardolo FLMultiple roles of nitric oxide in the airways . Thorax. 2003;58:175-182.
15.
Kawashima S.,Yokoyama M.Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:998-1005.
16.
Maiorana A., O'Driscoll G.,Taylor R., Green D.Exercise and the nitric oxide vasodilator system. Sports Med.2003;33:1013-1035.
17.
Brunner H., Cockcroft JR, Deanfield J.,et al .Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension . J Hypertens.2005;23:233-246.
18.
Lapu-Bula R., Ofili E.From hypertension to heart failure: role of nitric oxide-mediated endothelial dysfunction and emerging insights from myocardial contrast echocardiography . Am J Cardiol.2007;99:7D-14D.
19.
Miwa K., Fujita M., Sasayama S.Recent insights into the mechanisms, predisposing factors, and racial differences of coronary vasospasm. Heart Vessels. 2005 ;20:1-7.
20.
Hart CMNitric oxide in adult lung disease. Chest. 1999;115:1407-1417.
21.
Buhimschi IA , Saade GR, Chwalisz K., Garfield REThe nitric oxide pathway in pre-eclampsia: pathophysiological implications. Hum Reprod Update. 1998;4:25-42.
22.
Hajjar I., Kotchen TATrends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA.2003;290:199-206.
23.
Schocken DD , Arrieta MI, Leaverton PE, Ross EAPrevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol.1992;20:301-306.
24.
Alderman MH , Cohen HW, Madhavan S.Myocardial infarction in treated hypertensive patients: the paradox of lower incidence but higher mortality in young blacks compared with whites. Circulation. 2000;101:1109-1114.
25.
Kissela B., Schneider A., Kleindorfer D., et al. Stroke in a biracial population: the excess burden of stroke among blacks. Stroke. 2004;35:426-431.
26.
Bragulat E. , de la Sierra A., Antonio MT, Coca A.Endothelial dysfunction in salt-sensitive essential hypertension. Hypertension. 2001 ;37:444-448.
27.
McDaniel M. , Paxson C., Waldfogel J.Racial disparities in childhood asthma in the United States: evidence from the National Health Interview Survey, 1997 to 2003. Pediatrics. 2006;117:e868-e877.
28.
McBean AM, Li S., Gilbertson DT, Collins AJDifferences in diabetes prevalence, incidence, and mortality among the elderly of four racial/ethnic groups: whites, blacks, Hispanics, and Asians. Diabetes Care. 2004 ;27:2317-2324.
29.
Ferdinand KC , Clark LTThe epidemic of diabetes mellitus and the metabolic syndrome in African Americans. Rev Cardiovasc Med.2004;5(suppl 3):S28-S33.
30.
McKeigue PM , Shah B., Marmot MGRelation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Lancet. 1991;337: 382-386.
31.
Balarajan R.Ethnic differences in mortality from ischaemic heart disease and cerebrovascular disease in England and Wales. BMJ.1991;302:560-564.
32.
Benjamin IJ , Arnett DK, Loscalzo J.Discovering the full spectrum of cardiovascular disease: Minority Health Summit 2003: report of the Basic Science Writing Group. Circulation. 2005;111:e120-e123.
33.
Alderton WK , Cooper CE, Knowles RGNitric oxide synthases: structure, function and inhibition. Biochem J.2001; 357:593-615.
34.
Forstermann U., Gath I., Schwarz P., Closs EI, Kleinert H.Isoforms of nitric oxide synthase: properties, cellular distribution and expressional control. Biochem Pharmacol.1995;50: 1321-1332.
35.
Kone BCProtein-protein interactions controlling nitric oxide synthases. Acta Physiol Scand.2000;168:27-31.
36.
Fulton D., Gratton JP, Sessa WCPost-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough?J Pharmacol Exp Ther.2001;299:818-824.
37.
Minshall RD , Sessa WC, Stan RV, Anderson RG, Malik ABCaveolin regulation of endothelial function . Am J Physiol Lung Cell Mol Physiol. 2003 ;285:L1179-L1183.
38.
Mount PF, Kemp BE, Power DARegulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation . J Mol Cell Cardiol. 2007;42:271-279.
39.
Fulton D., Gratton JP, McCabe TJ, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999;399:597-601.
40.
Chen ZP, Mitchelhill KI, Michell BJ, et al. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett.1999;443:285-289.
41.
Butt E., Bernhardt M., Smolenski A., et al. Endothelial nitric-oxide synthase (type III) is activated and becomes calcium independent upon phosphorylation by cyclic nucleotide-dependent protein kinases.JBiol Chem. 2000;275:5179-5187.
42.
Michell BJ, Chen Z., Tiganis T., et al. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J Biol Chem.2001;276:17625-17628.
43.
Haynes MP, Russell KS, Bender JRMolecular mechanisms of estrogen actions on the vasculature. J Nucl Cardiol. 2000;7: 500-508.
44.
Hafezi-Moghadam A., Simoncini T., Yang Z., et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med.2002;8:473-479.
45.
Montagnani M., Chen H., Barr VA, Quon MJInsulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). J Biol Chem.2001;276:30392-30398.
46.
Michell BJ, Griffiths JE, Mitchelhill KI, et al. The Akt kinase signals directly to endothelial nitric oxide synthase. Curr Biol. 1999;9:845-848.
47.
Dimmeler S.,Assmus B., Hermann C., Haendeler J.,Zeiher AMFluid shear stress stimulates phosphorylation of Akt in human endothelial cells: involvement in suppression of apoptosis. Circ Res. 1998;83:334-341.
48.
Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., Zeiher AMActivation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399: 601-605.
49.
Rahman I., Biswas SK, Kode A.Oxidant and antioxidant balance in the airways and airway diseases. Eur J Pharmacol.2006; 533:222-239.
50.
Mates JMEffects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology. Toxicology. 2000;153:83-104.
Griendling KK, FitzGerald GAOxidative stress and cardiovascular injury: part I: basic mechanisms and in vivo monitoring of ROS. Circulation . 2003;108:1912-1916.
53.
Griendling KK, FitzGerald GAOxidative stress and cardiovascular injury: part II: animal and human studies. Circulation. 2003;108:2034-2040.
54.
Roberts JM, Hubel CAOxidative stress in preeclampsia. Am J Obstet Gynecol.2004;190:1177-1178.
55.
Myatt L., Cui X.Oxidative stress in the placenta. Histochem Cell Biol.2004;122:369-382.
56.
Hare JMNitroso-redox balance in the cardiovascular system. N Engl J Med.2004;351:2112-2114.
57.
Kozak AJ, Liu F., Funovics P., Jacoby A., Kubant R., Malinski T.Role of peroxynitrite in the process of vascular tone regulation by nitric oxide and prostanoids—a nanotechnological approach. Prostaglandins Leukot Essent Fatty Acids. 2005;72:105-113.
58.
Forstermann U., Closs EI, Pollock JS, et al. Nitric oxide synthase isozymes: characterization, purification, molecular cloning, and functions. Hypertension . 1994;23:1121-1131.
59.
Wang SZ, Zhu SZ, el-Fakahany EEEfficient coupling of m5 muscarinic acetylcholine receptors to activation of nitric oxide synthase. J Pharmacol Exp Ther.1994;268:552-557.
60.
Harris MB, Ju H., Venema VJ, et al. Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. J Biol Chem.2001;276: 16587-16591.
61.
Isenovic E. , Walsh MF, Muniyappa R., Bard M., Diglio CA, Sowers JRPhosphatidylinositol 3-kinase may mediate isoproterenol-induced vascular relaxation in part through nitric oxide production . Metabolism. 2002;51:380-386.
62.
Ito Y., Kitamura K., Kuriyama H.Effects of acetylcholine and catecholamines on the smooth muscle cell of the porcine coronary artery. J Physiol.1979;294:595-611.
63.
Tagawa T., Imaizumi T., Endo T., Shiramoto M., Harasawa Y., Takeshita A.Role of nitric oxide in reactive hyperemia in human forearm vessels. Circulation. 1994;90:2285-2290.
64.
Dakak N., Husain S., Mulcahy D., et al. Contribution of nitric oxide to reactive hyperemia: impact of endothelial dysfunction. Hypertension. 1998 ;32:9-15.
65.
Dietz NM, Rivera JM, Eggener SE, Fix RT, Warner DO, Joyner MJNitric oxide contributes to the rise in forearm blood flow during mental stress in humans. J Physiol.1994; 480(pt 2):361-368.
66.
Cardillo C. , Kilcoyne CM, Quyyumi AA, Cannon ROIII, Panza JARole of nitric oxide in the vasodilator response to mental stress in normal subjects. Am J Cardiol.1997;80: 1070-1074.
67.
Endo T., Imaizumi T., Tagawa T., Shiramoto M., Ando S., Takeshita A.Role of nitric oxide in exercise-induced vasodilation of the forearm. Circulation. 1994;90:2886-2890.
68.
Bassett DR Jr, Duey WJ, Walker AJ, Howley ET, Bond V.Racial differences in maximal vasodilatory capacity of forearm resistance vessels in normotensive young adults. Am J Hypertens.1992;5:781-786.
69.
Lang CC, Stein CM, Brown RM, et al. Attenuation of isoproterenol-mediated vasodilatation in blacks . N Engl J Med.1995;333:155-160.
70.
Hinderliter AL, Sager AR, Sherwood A., Light KC, Girdler SS, Willis PWEthnic differences in forearm vasodilator capacity. Am J Cardiol.1996;78:208-211.
71.
Bond V. Jr, Thompson GD, Franks BD, Tearney RJ, Adams RG,Vaccaro P.Racial differences in minimum lower leg vascular resistance in normotensive young adults with positive and negative parental histories of hypertension. J Cardiovasc Risk. 1996;3:423-426.
72.
Stein CM, Lang CC, Nelson R., Brown M., Wood AJVasodilation in black Americans: attenuated nitric oxide-mediated responses . Clin Pharmacol Ther.1997;62:436-443.
73.
Cardillo C. , Kilcoyne CM, Cannon ROIII, Panza JARacial differences in nitric oxide—mediated vasodilator response to mental stress in the forearm circulation. Hypertension. 1998; 31:1235-1239.
74.
Cardillo C. , Kilcoyne CM, Cannon ROIII, Panza JAAttenuation of cyclic nucleotide-mediated smooth muscle relaxation in blacks as a cause of racial differences in vasodilator function. Circulation. 1999;99:90-95.
75.
Jones DS,Andrawis NS,Abernethy DRImpaired endothelial-dependent forearm vascular relaxation in black Americans . Clin Pharmacol Ther.1999;65:408-412.
76.
Stein CM, Lang CC, Singh I., He HB,Wood AJIncreased vascular adrenergic vasoconstriction and decreased vasodilation in blacks: additive mechanisms leading to enhanced vascular reactivity. Hypertension. 2000;36:945-951.
77.
Gainer JV, Stein CM, Neal T., Vaughan DE, Brown NJInteractive effect of ethnicity and ACE insertion/deletion polymorphism on vascular reactivity. Hypertension. 2001;37:46-51.
78.
Rosenbaum DA , Pretorius M., Gainer JV, et al. Ethnicity affects vasodilation, but not endothelial tissue plasminogen activator release, in response to bradykinin. Arterioscler Thromb Vasc Biol. 2002;22:1023-1028.
79.
Duck MM, Hoffman RPImpaired endothelial function in healthy African-American adolescents compared with Caucasians. J Pediatr.2007;150:400-406.
80.
Kahn DF, Duffy SJ, Tomasian D., et al. Effects of black race on forearm resistance vessel function . Hypertension. 2002;40: 195-201.
81.
Androne AS, Hryniewicz K., Hudaihed A., et al. Comparison of metabolic vasodilation in response to exercise and ischemia and endothelium-dependent flow-mediated dilation in African-American versus non-African-American patients with chronic heart failure. Am J Cardiol.2006;97:685-689.
82.
Murphy C., Kanaganayagam GS, Jiang B., et al. Vascular dysfunction and reduced circulating endothelial progenitor cells in young healthy UK South Asian men. Arterioscler Thromb Vasc Biol. 2007;27:936-942.
83.
Lteif AA, Han K., Mather KJObesity, insulin resistance, and the metabolic syndrome: determinants of endothelial dysfunction in whites and blacks. Circulation. 2005;112:32-38.
84.
Kalra L., Rambaran C., Chowienczyk P., et al. Ethnic differences in arterial responses and inflammatory markers in Afro-Caribbean and Caucasian subjects. Arterioscler Thromb Vasc Biol. 2005;25:2362-2367.
85.
Kalra L., Rambaran C., Iveson E., et al. The role of inheritance and environment in predisposition to vascular disease in people of African descent. J Am Coll Cardiol.2006;47: 1126-1133.
86.
Houghton JL , Carr AA, Strogatz DS, et al. Coronary vasomotor reactivity among normotensive African and white American subjects with chest pain. Am J Med.1997;102:245-251.
87.
Houghton JL , Philbin EF, Strogatz DS, et al. The presence of African American race predicts improvement in coronary endothelial function after supplementary L-arginine. J Am Coll Cardiol.2002;39:1314-1322.
88.
Houghton JL , Smith VE, Strogatz DS, Henches NL, Breisblatt WM, Carr AAEffect of African-American race and hypertensive left ventricular hypertrophy on coronary vascular reactivity and endothelial function. Hypertension. 1997;29: 706-714.
89.
Houghton JL , Strogatz DS, Torosoff MT, et al. AfricanAmericans with LVH demonstrate depressed sensitivity of the coronary microcirculation to stimulated relaxation. Hypertension. 2003;42:269-276.
90.
Melikian N. , Wheatcroft SB, Ogah OS, et al. Asymmetric dimethylarginine and reduced nitric oxide bioavailability in young Black African men. Hypertension. 2007;49:873-877.
91.
Perregaux D. , Chaudhuri A., Rao S., et al. Brachial vascular reactivity in blacks . Hypertension. 2000;36:866-871.
92.
Campia U., Choucair WK, Bryant MB, Waclawiw MA, Cardillo C., Panza JAReduced endothelium-dependent and -independent dilation of conductance arteries in African Americans. J Am Coll Cardiol.2002 ;40:754-760.
93.
Wu HD, Berglund L., Dimayuga C., et al. High lipoprotein(a) levels and small apolipoprotein(a) sizes are associated with endothelial dysfunction in a multiethnic cohort. J Am Coll Cardiol.2004;43:1828-1833.
94.
Marchesi S. , Lupattelli G., Sensini A., et al. Racial difference in endothelial function: role of the infective burden. Atherosclerosis. 2007;191:227-234.
95.
Loehr LR, Espeland MA, Sutton-Tyrrell K., Burke GL, Crouse JR III, Herrington DMRacial differences in endothelial function in postmenopausal women. Am Heart J.2004;148:606-611.
96.
Gokce N., Holbrook M., Duffy SJ, et al. Effects of race and hypertension on flow-mediated and nitroglycerin-mediated dilation of the brachial artery. Hypertension. 2001;38:1349-1354.
97.
Jawa A., Nachimuthu S., Pendergrass M., Asnani S., Fonseca V.Impaired vascular reactivity in African-American patients with type 2 diabetes mellitus and microalbuminuria or proteinuria despite angiotensin-converting enzyme inhibitor therapy. J Clin Endocrinol Metab.2006;91:31-35.
98.
Raji A., Gerhard-Herman MD, Warren M., et al. Insulin resistance and vascular dysfunction in nondiabetic Asian Indians. J Clin Endocrinol Metab.2004;89:3965-3972.
99.
Chambers JC , McGregor A., Jean-Marie J., Kooner JSAbnormalities of vascular endothelial function may contribute to increased coronary heart disease risk in UK Indian Asians . Heart. 1999;81:501-504.
100.
Lieberman EH, Gerhard MD, Uehata A., et al. Flow-induced vasodilation of the human brachial artery is impaired in patients 40 years of age with coronary artery disease. Am J Cardiol.1996;78:1210-1214.
101.
Joannides R., Haefeli WE, Linder L., et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. 1995;91:1314-1319.
102.
Sharma A., Basu S., Padginton C., Sung BH, Wilson MF, Dandona P.Absence of Insulin-Mediated Vasodilation in African Americans. Paper presented at: 10th International Congress of Endocrinology ; 1996; San Francisco, CA.
103.
Taylor AL, Ziesche S.,Yancy C., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med.2004;351:2049-2057.
104.
Wallace TW , Drazner MHThe impact of race on response to RAAS inhibition . Curr Heart Fail Rep. 2005;2:72-77.
105.
Exner DV, Dries DL, Domanski MJ, Cohn JNLesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med.2001;344:1351-1357.
106.
Ke RW, Todd Pace D, Ahokas RA. Effect of short-term hormone therapy on oxidative stress and endothelial function in African American and Caucasian postmenopausal women. Fertil Steril.2003;79:1118-1122.
107.
Fenster CP , Darley-Usmar VM, Landar AL, et al.Weight loss and race modulate nitric oxide metabolism in overweight women. Free Radic Biol Med.2004;37:695-702.
108.
Earle KA, Mehrotra S., Dalton RN, Denver E., Swaminathan R.Defective nitric oxide production and functional renal reserve in patients with type 2 diabetes who have microalbuminuria of African and Asian compared with white origin. J Am Soc Nephrol.2001;12:2125-2130.
109.
Jackson RW, Treiber FA, Harshfield GA, Waller JL, Pollock JS, Pollock DMUrinary excretion of vasoactive factors are correlated to sodium excretion . Am J Hypertens.2001;14:1003-1006.
110.
Malhotra S., Poole J., Davis H., et al. Effects of NOS3 Glu298Asp polymorphism on hemodynamic reactivity to stress: influences of ethnicity and obesity. Hypertension . 2004;44:866-871.
111.
Cicinelli E., Ignarro LJ, Matteo MG, Galantino P., Schonauer LM, Falco N.Effects of estrogen replacement therapy on plasma levels of nitric oxide in postmenopausal women. Am J Obstet Gynecol.1999;180:334-339.
112.
Kalinowski L., Dobrucki IT, Malinski T.Race-specific differences in endothelial function: predisposition of African Americans to vascular diseases. Circulation. 2004;109: 2511-2517.
113.
Mason RP, Kalinowski L., Jacob RF, Jacoby AM, Malinski T.Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation. 2005;112:3795-3801.
114.
Zhou L., Xiang W., Potts J., et al. Reduction in extracellular superoxide dismutase activity in African-American patients with hypertension. Free Radic Biol Med.2006;41:1384-1391.
115.
Su YR, Rutkowski MP, Klanke CA, et al. A novel variant of the beta-subunit of the amiloride-sensitive sodium channel in African Americans. J Am Soc Nephrol.1996;7:2543-2549.
116.
Xie HG , Kim RB, Wood AJ, Stein CMMolecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol.2001;41:815-850.
SandrimVC, Coelho EB, Nobre F.,Arado GM, LanchoteVL, Tanus-Santos JESusceptible and protective eNOS haplotypes in hypertensive black and white subjects. Atherosclerosis. 2006; 186:428-432.
119.
Zhu H. , Wang X., Dong Y., Treiber FA, Snieder H.Influence of the eNOS gene on development of blood pressure and left ventricular mass: longitudinal findings in multiethnic youth. PharmacogenetGenomics. 2005;15:669-675.
120.
Soma M., Nakayama T., Kanmatsuse K.Nitric oxide synthase gene polymorphism and its influence on cardiovascular disease. Curr Opin Nephrol Hypertens. 1999 ;8:83-87.
121.
Sandrim VC , Yugar-Toledo JC, Desta Z., Flockhart DA, Moreno H Jr,Tanus-Santos JEEndothelial nitric oxide synthase haplotypes are related to blood pressure elevation but not to resistance to antihypertensive drug therapy. J Hypertens.2006;24:2393-2397.
122.
Tsukada T. ,Yokoyama K., Arai T., et al. Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans. Biochem Biophys Res Commun.1998;245:190-193.
123.
Hoffmann IS ,Tavares-Mordwinkin R., Castejon AM, Alfieri AB, Cubeddu LXEndothelial nitric oxide synthase polymorphism, nitric oxide production, salt sensitivity and cardiovascular risk factors in Hispanics. J Hum Hypertens . 2005;19:233-240.
124.
Uwabo J., Soma M., Nakayama T., Kanmatsuse K.Association of a variable number of tandem repeats in the endothelial constitutive nitric oxide synthase gene with essential hypertension in Japanese. Am J Hypertens.1998;11:125-128.
125.
Pulkkinen A.,Viitanen L., Kareinen A., Lehto S.,Vauhkonen I., Laakso M.Intron 4 polymorphism of the endothelial nitric oxide synthase gene is associated with elevated blood pressure in type 2 diabetic patients with coronary heart disease. J Mol Med.2000;78:372-379.
126.
Nagassaki S., Metzger IF, Souza-Costa DC, Marroni AS, Uzuelli JA, Tanus-Santos JEeNOS genotype is without effect on circulating nitrite/nitrate level in healthy male population. Thromb Res.2005;115:375-379.
127.
Hwang JJ, Tsai CT, Yeh HM, et al. The 27-bp tandem repeat polymorphism in intron 4 of the endothelial nitric oxide synthase gene is not associated with coronary artery disease in a hospital-based Taiwanese population. Cardiology. 2002 ;97:67-72.
128.
Zintzaras E., Kitsios G., Stefanidis I.Endothelial NO synthase gene polymorphisms and hypertension: a meta-analysis. Hypertension. 2006;48:700-710.
129.
Casas JP, Cavalleri GL, Bautista LE, Smeeth L., Humphries SE, Hingorani ADEndothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review. Am J Epidemiol.2006;164:921-935.
130.
Marroni AS , Metzger IF, Souza-Costa DC, et al. Consistent interethnic differences in the distribution of clinically relevant endothelial nitric oxide synthase genetic polymorphisms. Nitric Oxide. 2005;12:177-182.
131.
Tanus-Santos JE, Desai M., Flockhart DAEffects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. Pharmacogenetics . 2001;11:719-725.
132.
Li R., Lyn D., Lapu-Bula R., et al. Relation of endothelial nitric oxide synthase gene to plasma nitric oxide level, endothelial function, and blood pressure in African Americans . Am J Hypertens.2004;17:560-567.
133.
Galvin VB, Barakat H., Kemeny G., Macdonald KG, Pories WJ, Hickner RCEndothelial nitric oxide synthase content in adipose tissue from obese and lean African American and white American women. Metabolism . 2005;54:1368-1373.
134.
Leopold JA , ZhangYY, Scribner AW, Stanton RC, Loscalzo J. Glucose-6-phosphate dehydrogenase overexpression decreases endothelial cell oxidant stress and increases bioavailable nitric oxide. Arterioscler Thromb Vasc Biol. 2003;23:411-417.
135.
Hubel CAOxidative stress in the pathogenesis of preeclampsia. Proc Soc Exp Biol Med.1999;222:222-235.
136.
Magness RRMaternal cardiovascular and other physiologic responses to the endocrinology of pregnancy. In: Bazer FW, ed. The Endocrinology of Pregnancy. Totowa, NJ: Human Press; 1999:507-539.
137.
Sladek SM, Magness RR, Conrad KPNitric oxide and pregnancy. Am J Physiol.1997;272:R441-R463.
138.
Yallampalli C. , Garfield REInhibition of nitric oxide synthesis in rats during pregnancy produces signs similar to those of preeclampsia. Am J Obstet Gynecol.1993;169:1316-1320.
139.
Pettersson A. , Hedner T., Milsom I.Increased circulating concentrations of asymmetric dimethyl arginine (ADMA), an endogenous inhibitor of nitric oxide synthesis , in preeclampsia. Acta Obstet Gynecol Scand . 1998;77:808-813.
140.
Holden DP, Fickling SA, Whitley GS, Nussey SSPlasma concentrations of asymmetric dimethylarginine, a natural inhibitor of nitric oxide synthase, in normal pregnancy and preeclampsia . Am J Obstet Gynecol.1998;178:551-556.
141.
Rytlewski K., Olszanecki R., Korbut R., Zdebski Z.Effects of prolonged oral supplementation with l-arginine on blood pressure and nitric oxide synthesis in preeclampsia . Eur J Clin Invest.2005;35:32-37.
142.
Guendelman S., Thornton D., Gould J., Hosang N.Obstetric complications during labor and delivery: assessing ethnic differences in California. Womens Health Issues. 2006;16:189-197.
143.
Tucker MJ, Berg CJ, Callaghan WM, Hsia J.The Black-White disparity in pregnancy-related mortality from 5 conditions: differences in prevalence and case-fatality rates. Am J Public Health.2007;97:247-251.
144.
Bryant AS, Seely EW, Cohen A., Lieberman E.Patterns of pregnancy-related hypertension in black and white women. Hypertens Pregnancy. 2005;24:281-290.
145.
Tanaka M., Jaamaa G., Kaiser M., et al. Racial disparity in hypertensive disorders of pregnancy in New York State: a 10-year longitudinal population-based study. Am J Public Health.2007;97:163-170.
146.
Shen JJ, Tymkow C., MacMullen N.Disparities in maternal outcomes among four ethnic populations. Ethn Dis.2005; 15:492-497.
147.
Van Buren GA,Yang DS, Clark KEEstrogen-induced uterine vasodilatation is antagonized by L-nitroarginine methyl ester, an inhibitor of nitric oxide synthesis. Am J Obstet Gynecol.1992;167:828-833.
148.
Williams DJ , Vallance PJ, Neild GH, Spencer JA, Imms FJNitric oxide-mediated vasodilation in human pregnancy. Am J Physiol.1997;272:H748-H752.
149.
Miller SL, Jenkin G., Walker DWEffect of nitric oxide synthase inhibition on the uterine vasculature of the late-pregnant ewe. Am J Obstet Gynecol.1999 ;180: 1138-1145.
150.
Rosenfeld CR, Cox BE, Roy T., Magness RRNitric oxide contributes to estrogen-induced vasodilation of the ovine uterine circulation. J Clin Invest.1996;98:2158-2166.
151.
Buhimschi I., Ali M., Jain V., Chwalisz K., Garfield REDifferential regulation of nitric oxide in the rat uterus and cervix during pregnancy and labour. Hum Reprod. 1996;11:1755-1766.
152.
Sladek SM, Regenstein AC, Lykins D., Roberts JMNitric oxide synthase activity in pregnant rabbit uterus decreases on the last day of pregnancy. Am J Obstet Gynecol.1993; 169:1285-1291.
153.
Gibson CS, MacLennan AH, Dekker GA, et al. Genetic polymorphisms and spontaneous preterm birth. Obstet Gynecol.2007;109:384-391.
154.
Lade JA, Moses EK, Guo G., et al.The eNOS gene: a candidate for the preeclampsia susceptibility locus?Hypertens Pregnancy. 1999;18:81-93.
155.
Vita JANitric oxide-dependent vasodilation in human subjects. Methods Enzymol.2002;359:186-200.
